Evidence map›Paper›PMID 9716487›Full record

ReviewThe Biochemical journal1998

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

P C Heinrich, I Behrmann, G Müller-Newen, F Schaper, L Graeve

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Biochemical journal, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 774 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
774citing papers in PubMed, 2 pooled it
33.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

774 citing papers in PubMed, 2 syntheses or guidelines pooled it, 2,119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. S100A9 Induces RANKL Expression in Osteocytes Utilizing IL-6/sIL-6R Combination and gp130 Signaling Pathways.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  5. Review
  6. Tocilizumab for severe and refractory mucous membrane pemphigoid.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  7. Review
  8. Molecules (Basel, Switzerland) · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

714 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

P C HeinrichInstitut für Biochemie, RWTH Aachen, Universitätsklinikum, Pauwelsstrasse 30, D-52057 Aachen, Germany. Heinrich@RWTH-Aachen.de
I Behrmann
G Müller-Newen
F Schaper
L Graeve
Universitätsklinikum Aachen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The family of cytokines signalling through the common receptor subunit gp130 comprises interleukin (IL)-6, IL-11, leukaemia inhibitory factor, oncostatin M, ciliary neurotrophic factor and cardiotrophin-1. These so-called IL-6-type cytokines play an important role in the regulation of complex cellular processes such as gene activation, proliferation and differentiation. The current knowledge on the signal-transduction mechanisms of these cytokines from the plasma membrane to the nucleus is reviewed. In particular, we focus on the assembly of receptor complexes after ligand binding, the activation of receptor-associated kinases of the Janus family, and the recruitment and phosphorylation of transcription factors of the STAT family, which dimerize, translocate to the nucleus, and bind to enhancer elements of respective target genes leading to transcriptional activation. The important players in the signalling pathway, namely the cytokines and the receptor components, the Janus kinases Jak1, Jak2 and Tyk2, the signal transducers and activators of transcription STAT1 and STAT3 and the tyrosine phosphatase SHP2 [SH2 (Src homology 2) domain-containing tyrosine phosphatase] are introduced and their structural/functional properties are discussed. Furthermore, we review various mechanisms involved in the termination of the IL-6-type cytokine signalling, namely the action of tyrosine phosphatases, proteasome, Jak kinase inhibitors SOCS (suppressor of cytokine signalling), protein inhibitors of activated STATs (PIAS), and internalization of the cytokine receptors via gp130. Although all IL-6-type cytokines signal through the gp130/Jak/STAT pathway, the comparison of their physiological properties shows that they elicit not only similar, but also distinct, biological responses. This is reflected in the different phenotypes of IL-6-type-cytokine knock-out animals.

Indexed as

Signal TransductionAnimalsAntigens, CDCell DifferentiationCell DivisionCell MembraneCell NucleusCytokine Receptor gp130CytokinesDNA-Binding ProteinsGene Expression RegulationHumansInterleukin-6Membrane GlycoproteinsModels, MolecularProtein ConformationAntigens, CDCytokine Receptor gp130CytokinesDNA-Binding ProteinsIL6ST protein, humanInterleukin-6Membrane GlycoproteinsProtein-Tyrosine KinasesReceptors, CytokineTrans-Activators

Identifiers

PMID9716487
PMCPMC1219691
OpenAlexW1779691448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.